A
Alain M. Schoepfer
Researcher at University Hospital of Lausanne
Publications - 321
Citations - 16599
Alain M. Schoepfer is an academic researcher from University Hospital of Lausanne. The author has contributed to research in topics: Eosinophilic esophagitis & Medicine. The author has an hindex of 51, co-authored 265 publications receiving 13251 citations. Previous affiliations of Alain M. Schoepfer include University of Zurich & McMaster University.
Papers
More filters
Journal ArticleDOI
Diagnostic delay in patients with eosinophilic esophagitis has not changed since first description 30 years ago.
Fritz Murray,Andrea S. Kreienbuehl,Thomas Greuter,Simon Nennstiel,Ekaterina Safroneeva,Catherine Saner,Valeria Schindler,Christoph Schlag,Alain M. Schoepfer,Philipp Schreiner,Alex Straumann,Luc Biedermann +11 more
TL;DR: Substantial efforts are warranted to increase awareness for EoE and its hallmark symptom, solid-food dysphagia, as an age-independent red-flag symptom amongst health-care professionals and presumable the general population alike in order to lower risk of long-term complications.
Creating a multi-center rare disease consortium - the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)
Katherine Cheng,Sandeep K. Gupta,Susanna Kantor,Jonathan Kuhl,Seema S. Aceves,Peter A Bonis,Kelley E. Capocelli,Christina L Carpenter,Mirna Chehade,Margaret H. Collins,Evan S. Dellon,Gary W. Falk,Rashmi Gopal-Srivastava,Nirmala Gonsalves,Ikuo Hirano,Eileen C. King,John Leung,Jeffrey P. Krischer,Vincent A. Mukkada,Alain M. Schoepfer,Jonathan M. Spergel,Alex Straumann,Guang Yu Yang,Glenn T. Furuta,Marc E. Rothenberg +24 more
TL;DR: This review focuses on CEGIR’s operating model and progress and how it facilitates a framework for exchange of ideas and stimulates research and innovation and provides a model for progress on other potential clinical areas.
Journal ArticleDOI
Sa1113 - Correlation Between Esophageal Distensibility and Objective Measures of Disease in Patients with Active Eosinophilic Esophagitis: A Post HOC Analysis of a Randomized, Placebo-Controlled, Phase 2 Dupilumab Trial
Ikuo Hirano,Jennifer D. Hamilton,Margaret H. Collins,Zhiyue Lin,Evan S. Dellon,Zhen Chen,Kathryn A. Peterson,Mirna Chehade,Alain M. Schoepfer,Ekaterina Safroneeva,Marc E. Rothenberg,Gary W. Falk,Yehudith Assouline-Dayan,Gianluca Pirozzi,Leda Mannent,Neil M.H. Graham,Marcella Ruddy,Allen Radin +17 more
Journal ArticleDOI
Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland
Katharina Guilcher,Nicolas Fournier,Alain M. Schoepfer,Susanne Schibli,Johannes Spalinger,Christian Braegger,Andreas Nydegger +6 more
TL;DR: In the past decade, a significant earlier use of anti-tumor necrosis factor-&agr; agents in pediatric patients with IBD was observed with steroid-sparing effect in patients with CD, however, this change was not associated with reduction of surgery.
Journal ArticleDOI
Long-Term Efficacy and Safety of RPC4046, an Anti-Interleukin-13 Monoclonal Antibody, in Patients With Eosinophilic Esophagitis: Results From the Open-Label Extension of the HEROES Study
Evan S. Dellon,Margaret H. Collins,Yehudith Assouline-Dayan,Larry Evans,Sandeep K. Gupta,Alain M. Schoepfer,Alex Straumann,Ekaterina Safroneeva,Amy Woo,Allan Olson,Gregory J. Opiteck,Richard Aranda,Ikuo Hirano +12 more
TL;DR: The measurement of drug-induced interferon-gamma releasing cells is another option to identify the culprit drug in severe cutaneous adverse reactions (SCARs) since drug provocation is contraindicated.